Received Jul 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 3 | Z003767 | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | — | OT |
no adverse event; HCP calling to report on the administration of an extra dose of VARIVAX to a patient. Patient inadvertently received 3 doses of VARIVAX. First and second dose on 02/02/2023 and 05/19/2023 respectively. The extra dose was administered on 5/28/2025. Co; This spontaneous report was received from a Nurse and refers to a 4-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 02-FEB-2023, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), Injection, (lot #, dose, strength, route of administration, anatomical location of vaccine and expiration date were not reported); On 19-MAY-2023, with the second dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #, dose, strength, route of administration, anatomical location of vaccine and expiration date were not reported); and on 28-MAY-2025, the patient inadvertently received a third dose (extra dose) with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), Injection (dose, strength, route of administration and anatomical location of vaccine were not reported), lot #Z003767, expiration date was reported as 30-JAN-2027, diluted with sterile diluent (MERCK STERILE DILUENT) (Lot# and expiration date were not reported) with no symptoms (no adverse event); all three doses were administered for prophylaxis.
Sterile diluent solution for injection